4月7日 - ** 生物技术公司CG Oncology CGON.O股价盘前上涨1%至67.57美元
** 券商HC Wainwright将CGON的目标价从80美元上调至100美元，重申 "买入 "评级
** 券商称，CGON的领先疗法 "cretostimogene "正在接受测试，以减少术后频繁复发的早期膀胱癌的肿瘤复发。
** 称复发而非疾病恶化是这一患者群体尚未满足的主要需求，持久控制将减少重复手术次数
** 经纪公司补充说，晚期试验需要显示出超越早期时间点的持续疗效，以超越历史化疗结果
** 截至上一交易日收盘，股价年累计上涨约 12%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.